Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

10-28 Earnings release - Q3 2026

More about the company

Market Cap	483M 50.36M 43.3M 40.74M 37.17M 69.37M 4.77B 69.73M 187M 2.44B 189M 185M 7.77B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	483M 50.36M 43.3M 40.74M 37.17M 69.37M 4.77B 69.73M 187M 2.44B 189M 185M 7.77B	EV / Sales 2026 *	3.78x	EV / Sales 2027 *	2.37x
Free-Float	40.74%	Yield 2026 *	-	Yield 2027 *	-

08-05	Senzime's Distribution Partner Wins Supply Contract from US Veterans Affairs Department	MT
08-05	Senzime wins five-year VA contract in the US	FW
08-05	Senzime Awarded National Supply Contract in the US	FW
08-05	Senzime AB And TrillaMed LLC Receives Exclusive 5-Year National Supply Contract With U.S. Department Of Veterans Affairs	CI
07-16	Senzime AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-16	Senzime AB, Q2 2026 Earnings Call, Jul 16, 2026
07-16	Senzime AB, Q2 2026 Earnings Call, Jul 16, 2026
07-16	Senzime cuts revenue but improves operating result	FW
07-16	Senzime Signs Development, Commercialization Deal With Philips Electronics Nederland	MT
07-16	Senzime, Philips Medical Systems Enter Development, Commercialization Partnership	RE
07-16	Senzime to develop new products with Philips	FW
07-15	Senzime AB and Philips Electronics Nederland, B.V. Enter Development and Commercialization Partnership	CI
06-29	Senzime AB Receives ANVISA Approval for Tetragraph System in Brazil	CI

25-09-04	Redeye Initiates Coverage of Senzime with a Target Value of SEK 12	FW
25-06-03	DNB Carnegie believes that Senzime's targeted issue is sufficient to achieve positive free cash flow.	FW
24-05-13	Senzime's order intake supports long-term growth case - Penser	FW
24-02-19	Strong growth expected from Senzime also in 2024 - Penser	FW
23-10-27	Penser reiterates motivated value for Senzime	FW

08-05	Senzime awarded exclusive 5-year national supply contract with U.S. Veterans Affairs through its partner TrillaMed	AQ
07-16	Interim report Q2 2026: Strong sensor sales and improved margins, despite continued U.S. monitor market headwinds	AQ
07-15	Senzime and Philips Medical Systems enter development and commercialization partnership	AQ
07-13	Senzime : Invitation to presentations of Senzime's second quarter 2026 report	PU
07-13	Invitation to presentations of Senzime’s second quarter 2026 report	AQ

Manager	Title	Age	Since
Philip Axel Wilhelm Siberg CEO	Chief Executive Officer	53	2023-05-02
Slavoljub Grujicic DFI	Director of Finance/CFO	56	2021-12-31
Fredrik Norrby CTO	Chief Tech/Sci/R&D Officer	50	2022-12-31

Senzime AB (publ) Stock Nasdaq Stockholm

Stocks

SE0002478776

Medical Equipment, Supplies & Distribution

Valuation : Senzime AB (publ)

Latest news : Senzime AB (publ)

Last Transcript : Senzime AB (publ)

Analysts' recommendations : Senzime AB (publ)

Press Releases : Senzime AB (publ)

Managers and Directors : Senzime AB (publ)

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Director	Title	Age	Since
Lars Adam Holger Dahlberg CHM	Chairman	53	2023-05-02
Sorin Brull BRD	Director/Board Member	70	2015-12-31
Eva Walde BRD	Director/Board Member	63	2020-03-04

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SENZIME AB (PUBL)	-.--%	-0.85%	-	-	53.19M
ABBOTT LABORATORIES	-2.59%	-4.39%	-20.63%	+4.82%	187B
MEDTRONIC PLC	-1.89%	+1.92%	-0.55%	+15.59%	120B
CENCORA, INC.	-1.89%	+0.34%	+11.01%	+82.23%	63.15B
HOYA CORPORATION	-3.40%	-5.18%	+13.70%	+44.83%	52.36B
BECTON, DICKINSON AND COMPANY	-3.05%	-4.79%	-6.91%	-32.94%	50.32B
DEXCOM, INC.	-3.83%	-7.17%	+4.99%	-19.43%	33.17B
MEDLINE INC.	-5.19%	-0.97%	-	-	32.1B
WEST PHARMACEUTICAL SERVICES, INC.	-0.65%	-0.99%	+34.71%	-16.37%	23.93B
TERUMO CORPORATION	-1.98%	-7.53%	-12.06%	+6.09%	22.7B
Average	-2.03%	-0.72%	+3.03%	+10.60%	65.07B
Weighted average by Cap.	-1.27%	-0.77%	-3.88%	+14.03%

	2026 *	2027 *
Net sales	128M 13.32M 11.46M 10.78M 9.84M 18.36M 1.26B 18.45M 49.41M 646M 50.03M 48.94M 2.05B	204M 21.29M 18.3M 17.22M 15.71M 29.32M 2.02B 29.47M 78.93M 1.03B 79.93M 78.18M 3.28B
Net income	-68.9M -7.19M -6.18M -5.82M -5.31M -9.9M -682M -9.95M -26.66M -348M -27M -26.41M -1.11B	-36.8M -3.84M -3.3M -3.11M -2.83M -5.29M -364M -5.32M -14.24M -186M -14.42M -14.1M -592M
Net Debt	-	-